BACKGROUND: Thiopurines are classically used in Crohn's disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage. AIM: To evaluate the evolving use of azathioprine (AZA) monotherapy in the era of biologics. METHODS: The study retrospectively analyzed clinical records of all CD patients who started treatment with AZA monotherapy at our center since 1990. Dates of starting AZA and treatment failure (TF) were collected. We defined AZA TF if it was withdrawn due to lack of efficacy or AE, or biologics were added. RESULTS: A total of 383 patients were included: 46.5% were males and mean age was 31 (range 17-84) years. Median follow-up was 43 (range 0.2-289) months. Overall, 147 patients (38%) experienced TF. Median cumulative survival time of AZA was 126 (95% CI 105-147) months. Proportion of patients with AZA TF increased along time: 7 patients in 1990-1995 (4.7% of all TF); 8 in 1996-2000 (5.4%); 22 in 2001-2005(15%); 41 in 2006-2010 (28%); 69 in 2011-2014 (47%) (p = 0.04). 7%, 21%, 4%, 45%, and 33.3% of patients moved to biologics in each period, respectively (χ2 = 13.07; p < 0.05). Seventy-four patients (18.4%) stopped AZA due to AE, and 73(19%) due to lack of efficacy. Regarding AZA indication, prevention of postoperative recurrence obtained better results than steroid dependency (p = 0.001); perianal fistulizing CD predicted poorer outcomes (p = 0.002). CONCLUSION: An important proportion of CD patients under AZA monotherapy experienced TF in our experience. Although AZA monotherapy remains useful for CD in the era of biologics, current clinical practice is shifting to anti-TNFα biologic drugs in an increasing proportion of patients.
BACKGROUND:Thiopurines are classically used in Crohn's disease (CD). Treatment fails in a proportion of patients either due to adverse events (AE) or lack of efficacy. Increasing use of anti-TNFα biologic drugs may have had impact on thiopurines usage. AIM: To evaluate the evolving use of azathioprine (AZA) monotherapy in the era of biologics. METHODS: The study retrospectively analyzed clinical records of all CDpatients who started treatment with AZA monotherapy at our center since 1990. Dates of starting AZA and treatment failure (TF) were collected. We defined AZA TF if it was withdrawn due to lack of efficacy or AE, or biologics were added. RESULTS: A total of 383 patients were included: 46.5% were males and mean age was 31 (range 17-84) years. Median follow-up was 43 (range 0.2-289) months. Overall, 147 patients (38%) experienced TF. Median cumulative survival time of AZA was 126 (95% CI 105-147) months. Proportion of patients with AZA TF increased along time: 7 patients in 1990-1995 (4.7% of all TF); 8 in 1996-2000 (5.4%); 22 in 2001-2005(15%); 41 in 2006-2010 (28%); 69 in 2011-2014 (47%) (p = 0.04). 7%, 21%, 4%, 45%, and 33.3% of patients moved to biologics in each period, respectively (χ2 = 13.07; p < 0.05). Seventy-four patients (18.4%) stopped AZA due to AE, and 73(19%) due to lack of efficacy. Regarding AZA indication, prevention of postoperative recurrence obtained better results than steroid dependency (p = 0.001); perianal fistulizing CD predicted poorer outcomes (p = 0.002). CONCLUSION: An important proportion of CDpatients under AZA monotherapy experienced TF in our experience. Although AZA monotherapy remains useful for CD in the era of biologics, current clinical practice is shifting to anti-TNFα biologic drugs in an increasing proportion of patients.
Entities:
Keywords:
Crohn’s disease; Thiopurine IBD; Thiopurine maintenance in Crohn’s disease
Authors: Florian Beigel; Anni Steinborn; Fabian Schnitzler; Cornelia Tillack; Simone Breiteneicher; Jestinah Mahachie John; Kristel Van Steen; Rüdiger P Laubender; Burkhard Göke; Julia Seiderer; Stephan Brand; Thomas Ochsenkühn Journal: Pharmacoepidemiol Drug Saf Date: 2014-04-30 Impact factor: 2.890
Authors: David S Kotlyar; James D Lewis; Laurent Beaugerie; Ann Tierney; Colleen M Brensinger; Javier P Gisbert; Edward V Loftus; Laurent Peyrin-Biroulet; Wojciech C Blonski; Manuel Van Domselaar; Maria Chaparro; Sandipani Sandilya; Meenakshi Bewtra; Florian Beigel; Livia Biancone; Gary R Lichtenstein Journal: Clin Gastroenterol Hepatol Date: 2014-05-28 Impact factor: 11.382
Authors: María Chaparro; Ingrid Ordás; Eduard Cabré; Valle Garcia-Sanchez; Guillermo Bastida; Mireia Peñalva; Fernando Gomollón; Esther García-Planella; Olga Merino; Ana Gutiérrez; Maria Esteve; Lucia Márquez; Maria Garcia-Sepulcre; Joaquín Hinojosa; Isabel Vera; Fernando Muñoz; Juan L Mendoza; Jose L Cabriada; Miguel A Montoro; Manuel Barreiro-de Acosta; G Ceña; Cristina Saro; Xavier Aldeguer; Jesús Barrio; José Maté; Javier P Gisbert Journal: Inflamm Bowel Dis Date: 2013-06 Impact factor: 5.325
Authors: Laurent Peyrin-Biroulet; Walter Reinisch; Jean-Frederic Colombel; Gerassimos J Mantzaris; Asher Kornbluth; Robert Diamond; Paul Rutgeerts; Linda K Tang; Freddy J Cornillie; William J Sandborn Journal: Gut Date: 2013-08-23 Impact factor: 23.059